foxo4-dri senolytic peptide mechanism Class II senolytics inhibit survival pathways elicited by senescent FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. Buy FOXO4 DRI (Proxofim) Senolytic Peptide For Cellular Renewal Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


